Hints and tips:
...US merger and acquisition activity is getting a boost from an unlikely source: the Bank of Japan....
...Evan Seigerman, analyst at BMO Capital Markets, said the acquisition was a good fit for Pfizer and provided potential cost synergies....
...Unlike their big pharma cousins, they were better known for operational and financial acumen than cutting edge science....
...A chunky acquisition is needed to get growth up and build a company able to tackle larger, later-stage trials....
...The latter ambition comes with a $38bn price tag, which is what it has set aside for acquisitions and holdings through its gaming arm Savvy Games Group....
...The head of pharma company Sanofi said UK economic policy meant the country was falling behind in healthcare innovation....
...Its talent acquisition lead James Girling recently aimed a post on LinkedIn at tech workers fired by Twitter....
...He used to be the chief of French pharma giant Sanofi. Millennium Management, the multi-strategy hedge fund, has hired Justin Gmelich from King Street as its new co-chief investment officer....
...A key differentiating factor between these groups and Fosun issubsidiary Fosun Pharma....
...Mergers and acquisitions could be added on top of that amount, Isozaki said. Isozaki said he expected health sciences to bring in revenues of ¥200bn by 2027 with 15 per cent operating margin....
...Reliance has recently invested in healthcare companies including genetics group Strand Life Sciences, after buying a majority stake in pharma sales company Netmeds in 2020....
...Pharma group Takeda’s $65bn takeover of rival Shire, SoftBank’s $32bn deal to buy Arm, and Renesas Electronics $6.7bn acquisition of Integrated Device Technology for $6.7bn had ushered in a golden age of...
...“The EUSA Pharma acquisition represents an excellent opportunity to further expand and reinforce our portfolio in a new and under served therapeutic area (rare and niche oncology) with high potential growth...
...BUY: Indivior (INDV) Pharma group reports strong profits after an expensive legal battle with the US Department of Justice, writes Jemma Slingo....
...DD’s James Fontanella-Khan reports that $570bn worth of deals have been agreed this year across healthcare, pharma and biotech — 5,316 transactions, to be precise....
...(Nikkei Asia via FT) Biden’s blow to Big Pharma Patents are the lifeblood of the pharmaceuticals industry....
...The state-owned pharma group reportedly wants to take China Traditional Chinese Medicine private in a consortium. The parent company plans to offer at least HK$5.10 (US$0.66) per share for China TCM....
...The company is chasing mergers and acquisitions to overcome the looming Keytruda patent cliff, and in November spent $11.5bn on Acceleron Pharma, a biotech company that develops therapies for rare disease...
...Masayoshi Son’s conglomerate has officially launched a special purpose acquisition company....
...This is just the latest deal in a post-bubble spree spanning food, pharma and finance: think Daiichi-Sankyo and Ranbaxy, Kirin and Schincariol and Toshiba and Westinghouse....
...Investors will seek updates on Pfizer’s deal with Mylan on Thursday, while AbbVie’s acquisition of Allergan, which is nearing completion, will be in focus on Friday....
...The race to produce a coronavirus vaccine accelerated on Monday when the German group BioNTech announced a $135m partnership with Fosun Pharma of China to develop a Covid-19 vaccine, which it said could...
...Pfizer on Monday lowered its forecasts for the full year because of costs related to its joint venture with GSK and the acquisitions of Array and Therachon....
...Pfizer’s transaction with Mylan is the latest in a wave of large pharma and healthcare deals this year, including Bristol-Myers Squibb’s $90bn acquisition of biotech Celgene, Roche’s $4.8bn takeover of gene...
...The swashbuckling era for generic pharma companies has come to an close with a thud....
International Edition